Loading
Cut the fuel (oestrogen) and jam the engine (CDK4/6) at the same time.
This combination pairs CDK4/6 inhibitors with Endocrine therapy (SERMs, AIs, SERDs) in HR-positive / HER2-negative breast cancer, cutting the fuel and jamming the engine at once. The mechanism is that the oestrogen receptor drives cyclin D1 transcription, so blocking CDK4/6 shuts the downstream engine and residual ER signalling or an ESR1 mutation cannot bypass it, linking the Oestrogen receptor signalling and p53 / RB / cell-cycle checkpoint pathways. Multiple phase 3 trials (MONALEESA, MONARCH 2) showed improved progression-free and overall survival in advanced disease, and NATALEE and monarchE showed adjuvant benefit. The linked drugs are Palbociclib, Ribociclib and Abemaciclib, and the pairing is regarded as one of the most successful combinations in oncology.
Shares Ribociclib, Abemaciclib, Palbociclib, CDK4/6 inhibitors.
Shares Ribociclib, Abemaciclib, Palbociclib, Endocrine therapy (SERMs, AIs, SERDs).
Shares Ribociclib, Abemaciclib, Palbociclib, Endocrine therapy (SERMs, AIs, SERDs).
Shares Ribociclib, Abemaciclib, Palbociclib, Endocrine therapy (SERMs, AIs, SERDs).
Shares Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Abemaciclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Abemaciclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs).
Shares Ribociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.